


Remarks

The foregoing amendments to the specification are to insert the priority provisional application information, for which this application claims benefit. The Abstract has been added as a separate sheet, and should be inserted following the claims in the specification.

The amendments to the claims are to eliminate multiple dependencies and to place the claims in proper format. No new matter has been added.

Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,



Mark Milstead
Attorney for Applicants
Reg. No. 45,825

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(617) 871-4125

Date: May 26, 2006